Catalyst Wire Dossier Catalyst Wire Dossier

AC220

quizartinib · Daiichi Sankyo
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for AC220, covering 2019-02-12 to 2020-04-24. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status [Phase 1]

See pricing